Company news

Arcturus Therapeutics Holdings Inc. news in 2022

Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2022, newest first.

View company

Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 18, 2022

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

December 12, 2022

Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

November 8, 2022

Arcturus Therapeutics to Present at the Following Investor Conferences in November

November 6, 2022

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

October 31, 2022

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

October 25, 2022

Arcturus Therapeutics to Attend the Following Investor Conferences

September 26, 2022

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

August 30, 2022

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

August 17, 2022

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

August 8, 2022

Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

July 31, 2022

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2022

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

May 8, 2022

CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

May 4, 2022

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

April 26, 2022

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

April 19, 2022

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

March 24, 2022

Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

March 13, 2022

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

February 27, 2022

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

February 15, 2022

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 7, 2022

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

January 24, 2022

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

January 23, 2022

Calls in 2022

Decks in 2022